Watchlist Price Alert

Sanofi (SNY)

NASDAQ: SNY · Real-Time Price · USD

49.41

-0.26 (-0.52%)

At close: Jun 16, 2025, 2:16 PM

-0.52% (1D)

Bid	49.39
Market Cap	121.14B
Revenue (ttm)	43.77B
Net Income (ttm)	6.3B
EPS (ttm)	2.84
PE Ratio (ttm)	17.4
Forward PE	10.47
Analyst	Buy

Ask	49.41
Volume	1,159,484
Avg. Volume (20D)	2,709,157
Open	49.94
Previous Close	49.67
Day's Range	49.30 - 50.21
52-Week Range	45.80 - 60.12
Beta	0.41

About SNY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SNY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SNY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-5.69%

Sanofi shares are trading lower after the company ... Unlock content with Pro Subscription

1 month ago

-1.5%

Sanofi shares are trading lower after the company announced plans to invest at least $20 billion in the US through 2030.

News

Just now · zacks.com

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.

2 days ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to con...

6 days ago · seekingalpha.com

Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Sanofi (NASDAQ:SNY ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care Conference Call Parti...

1 week ago · investors.com

Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.

Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

1 week ago · cnbc.com

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca

The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus. The decision will allow the company to launc...

1 week ago · zacks.com

SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease

Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.

1 week ago · businesswire.com

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...

2 weeks ago · youtube.com

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

2 weeks ago · zacks.com

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.

1 week ago · youtube.com

Sanofi-Blueprint deal is a bullish signal about biotech M&A

The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. San...

Load More News